Sun Pharma reported a 27 per cent rise in Q1FY27 profit, driven by India and innovative medicines, while weakness in the US generics business continued to weigh on growth
Revenue from operations grew 10.5 per cent to ₹15,299.88 crore, while EBITDA margin narrowed by 220 basis points to 28.9 per cent as India sales rose 16 per cent
Among others, Manappuram Finance, Marico, Radico Khaitan, Redington, Welspun Corp, Laurus Labs and Sai Life Sciences also touched respective all-time highs in trade on Thursday.
Sun Pharma will launch the once-weekly diabetes treatment through Hypera Pharma as generic competition intensifies in Brazil's $413 million semaglutide market
Brokerages see an 11 per cent topline growth in Q1 FY27. HDFC Securities said that the US generic business will be muted due to the absence of gRevlimid, while the India business may grow 13 per cent.
Sun Pharma outlook: Analysts at Bajaj Broking flag a breakout above the monthly consolidation zone and the formation of higher-highs, higher-lows among key reasons for a bullish view on the stock.
From generics to global leadership, India's pharmaceutical industry has transformed since 1991. Its next challenge is becoming a global hub for breakthrough drug innovation
The Supreme Court allowed Intas Pharmaceuticals to market its cancer drug as Bevatas, rejecting Sun Pharma's plea while removing adverse observations against the company
The US President Donald Trump announced a proposal to impose phased tariff (up to 200%) regime on imported generic medicines aimed at encouraging pharmaceutical manufacturing within the United States.
Sun Pharma has secured South Africa's approval for its generic semaglutide injection and plans to launch the once-weekly diabetes treatment in the coming days
The approval makes South Africa the second market after India where the drugmaker has secured regulatory clearance for its generic version of semaglutide
Pharma stock rally: Orchid Pharma, Hikal, Unichem Labs, IOL Chemicals, SPARC, RPG Life Sciences and Acutaas Chemicals surged up to 13% in Wednesday's trade.
Stocks to watch today: Maruti Suzuki, Uno Minda, BHEL, Torrent Pharma, Tata Power, IHCL, IDFC First Bank, Kalyan Jewellers, Premier Energies, RCF, RRP Defense, among others, will be in focus today
In the past seven trading days, the Nifty Pharma index outperformed the market by soaring 5.4 per cent, as compared to 0.1 per cent decline in the Nifty 50.
Lupin, Intas Pharmaceuticals, Sun Pharma, MSN Laboratories, Natco Pharma, Zydus Life Sciences and Dr Reddy's Laboratories are some of the companies, the note said, that could potentially benefit.
